Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP)
CUSIP: 45339J105
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 113,183,288
- Total 13F shares
- 605,020
- Share change
- +5,105
- Total reported value
- $750,238
- Price per share
- $1.24
- Number of holders
- 17
- Value change
- +$5,985
- Number of buys
- 5
- Number of sells
- 8
Quarterly Holders Quick Answers
What is CUSIP 45339J105?
CUSIP 45339J105 identifies INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 45339J105:
Top shareholders of INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Glen R. Anderson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,190,400
|
$2,785,536 | — | 10 Aug 2023 | |
| Hoonmo Lee |
3/4/5
|
Director |
—
mixed-class rows
|
708,272
mixed-class rows
|
$1,626,157 | — | 04 Aug 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.23%
|
256,265
|
$543,282 | — | 30 Jun 2024 | |
| INVESTMENT HOUSE LLC |
13F
|
Company |
0.09%
|
102,437
|
$217,166 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
59,309
|
$125,755 | — | 30 Jun 2024 | |
| Pine Valley Investments Ltd Liability Co |
13F
|
Company |
0.04%
|
44,085
|
$93,461 | — | 30 Jun 2024 | |
| STRATEGY ASSET MANAGERS LLC |
13F
|
Company |
0.04%
|
45,336
|
$86,592 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.02%
|
26,600
|
$56,392 | — | 30 Jun 2024 | |
| Vivaldi Capital Management LP |
13F
|
Company |
0.02%
|
24,000
|
$50,880 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.02%
|
22,210
|
$47,085 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.01%
|
13,073
|
$27,715 | — | 30 Jun 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
4,102
|
$8,696 | — | 30 Jun 2024 | |
| Boyan Vesselinov Litchev |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
1,150
|
$2,691 | — | 01 Feb 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
884
|
$1,874 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
692
|
$1,467 | — | 30 Jun 2024 | |
| Brian O'Callaghan |
3/4/5
|
Director |
—
class O/S missing
|
13,750
|
$976 | — | 30 Sep 2022 | |
| Bangor Savings Bank |
13F
|
Company |
0%
|
400
|
$848 | — | 30 Jun 2024 | |
| Beaird Harris Wealth Management, LLC |
13F
|
Company |
0%
|
300
|
$636 | — | 30 Jun 2024 | |
| FMR LLC |
13F
|
Company |
0%
|
79
|
$167 | — | 30 Jun 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
64
|
$136 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
42
|
$89 | — | 30 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
15
|
$32 | — | 30 Jun 2024 | |
| MassMutual Private Wealth & Trust, FSB |
13F
|
Company |
0%
|
14
|
$30 | — | 30 Jun 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
7
|
$15 | — | 30 Jun 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0%
|
1
|
$2 | — | 30 Jun 2024 |
Institutional Holders of Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) as of Q3 2024
As of 30 Sep 2024,
Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
605,020 shares.
The largest 10 holders included
VANGUARD GROUP INC, INVESTMENT HOUSE LLC, GEODE CAPITAL MANAGEMENT, LLC, STRATEGY ASSET MANAGERS LLC, Pine Valley Investments Ltd Liability Co, RENAISSANCE TECHNOLOGIES LLC, Vivaldi Capital Management LP, CITADEL ADVISORS LLC, STATE STREET CORP, and Tower Research Capital LLC (TRC).
This page lists
18
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
21
Q3 2024 holders
17
Holder diff
-4
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.